They can recognize specific tumor antigens (e.g., CD19, HER2, GPC3) via CAR while retaining sensitivity to stress ligands such as MICA/B, establishing a “dual-activation” mechanism that drives robust cytotoxicity (18, 62). The gene discussed is ERBB2; the disease is neoplasm.